LifeSci Advisors Expands Presence Into Europe

Hires Senior Investor Relations Professional Chris Maggos NEW YORK, Nov. 17, 2015 (GLOBE NEWSWIRE) -- LifeSci Advisors, LLC, (the "Company" or "LifeSci") an investor relations and corporate communications firm focused on the life sciences sector, today announced the appointment of Chris Maggos as Managing Director, Europe and the expansion of the Company's services to European clientele. Mr...
Comunicato Precedente

next
Comunicato Successivo

next

Hires Senior Investor Relations Professional Chris Maggos

NEW YORK, Nov. 17, 2015 (GLOBE NEWSWIRE) -- LifeSci Advisors, LLC, (the "Company" or "LifeSci") an investor relations and corporate communications firm focused on the life sciences sector, today announced the appointment of Chris Maggos as Managing Director, Europe and the expansion of the Company's services to European clientele.

Mr. Maggos has over 20 years of experience in the life sciences industry covering business development, investor relations, public relations, journalism, and molecular biology. He is the founder of BioConfidant Sàrl, a Geneva-based strategic consulting firm that helped senior executives achieve their financing and partnering goals. Previously, while at Addex Therapeutics (SWX:ADXN), he was a member of the executive management board and held the positions of Head of Investor Relations & Communication from 2007 to 2010 and Director of Business Development from 2010 to 2013. Prior to Addex Therapeutics, Mr. Maggos was a journalist for BioCentury, a leading biotechnology trade publication, from 2001 to 2007. He began his career in the life sciences as a molecular biologist studying drug dependence at The Rockefeller University from 1993 to 1997, where he co-authored 12 peer-reviewed publications. He is also the co-Founder of the Alpine Institute for Drug Discovery, a not-for-profit social enterprise whose mission is to help commercialize academic discoveries. Mr. Maggos holds a BA in English Literature from Yale University, where he also completed pre-medical studies.

"Chris has an exceptional ability to help life sciences companies translate their value proposition to both the investment and scientific communities," said Andrew McDonald, Chief Executive Officer at LifeSci Advisors. "We have seen an increasing number of European companies seek introductions to the U.S. capital markets. With this hire, we look forward to expanding our presence in the region and serving as a valuable partner to those companies as they continue to develop their products and seek new sources of funding."

About LifeSci Advisors, LLC

LifeSci Advisors is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With local presence in New York, Boston, Chicago, and Geneva, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of Ph.D.s enables us to better understand our clients' R&D, regulatory, and commercial strategy, and our team of financial services, investor relations, and public relations specialists help our clients effectively communicate their strategies to the marketplace. This combination of life sciences, financial services, and investor relations expertise allows us to provide a valuable and unique service offering to our clients.

Visit our website:

www.lifesciadvisors.com

CONTACT: For further information, please contact:
         
         Andrew I. McDonald Ph.D.
         Chief Executive Officer
         Tel.: (646) 597-6987
         
         Michael Rice
         President
         Tel.: (646) 597-6979

Copyright GlobeNewswire


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire


[HUG#1967306]
Per maggiori informazioni
Sito Web
http://

Ufficio Stampa

 Thomson Reuters (Leggi tutti i comunicati)
3 Times Square
10036 New York, NY

Allegati
Slide ShowSlide Show
Non disponibili
;